Steroid Refractory GVHD
10
1
2
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
20.0%
2 terminated out of 10 trials
60.0%
-26.5% vs benchmark
30%
3 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
ECP Combination Study
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease